Metastatic Renal Cell Carcinoma

Also known as: Metastatic Renal cell carcinoma

DrugDrug NameDrug Description
DB00041AldesleukinAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
DB00112BevacizumabA recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
DB00603Medroxyprogesterone acetateMedroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP.
DrugDrug NameTargetType
DB00041AldesleukinInterleukin-2 receptor subunit betatarget
DB00041AldesleukinInterleukin-2 receptor subunit alphatarget
DB00041AldesleukinCytokine receptor common subunit gammatarget
DB00041AldesleukinProstaglandin G/H synthase 2enzyme
DB00041AldesleukinCytosolic phospholipase A2enzyme
DB00041AldesleukinCytochrome P450 3A4enzyme
DB00041AldesleukinXanthine dehydrogenase/oxidaseenzyme
DB00041AldesleukinCytochrome P450 2E1enzyme
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00603Medroxyprogesterone acetateProgesterone receptortarget
DB00603Medroxyprogesterone acetateEstrogen receptor alphatarget
DB00603Medroxyprogesterone acetateCytochrome P450 3A4enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 2C8enzyme
DB00603Medroxyprogesterone acetate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 2C9enzyme
DrugDrug NamePhaseStatusCount
DB05182AS14091Completed1
DB00041Aldesleukin1Recruiting1
DB00112Bevacizumab1Completed1
DB08875Cabozantinib1Recruiting1
DB00531Cyclophosphamide1Recruiting1
DB00531Cyclophosphamide1Withdrawn1
DB11651Dactolisib1Completed1
DB01590Everolimus1Completed2
DB01099Flucytosine1Active Not Recruiting1
DB01073Fludarabine1Recruiting1
DB14865Human interleukin-21Withdrawn1
DB06186Ipilimumab1Recruiting2
DB09035Nivolumab1Recruiting3
DB06589Pazopanib1Active Not Recruiting1
DB08913Radium Ra 223 Dichloride1Active Not Recruiting1
DB09566Radium Ra 223 Dichloride1Active Not Recruiting1
DB00398Sorafenib1Active Not Recruiting1
DB01268Sunitinib1Completed1
DB15331Vocimagene amiretrorepvec1Active Not Recruiting1
DB00041Aldesleukin1 / 2Active Not Recruiting1
DB00041Aldesleukin1 / 2Completed1
DB08875Cabozantinib1 / 2Recruiting1
DB01590Everolimus1 / 2Completed1
DB05304Girentuximab1 / 2Completed1
DB14865Human interleukin-21 / 2Recruiting1
DB01611Hydroxychloroquine1 / 2Active Not Recruiting1
DB09570Ixazomib1 / 2Terminated1
DB09078Lenvatinib1 / 2Completed1
DB09037Pembrolizumab1 / 2Recruiting2
DB023422-Methoxyestradiol2Completed1
DB04998AGRO1002Unknown Status1
DB00041Aldesleukin2Completed1
DB00041Aldesleukin2Unknown Status1
DB00126Ascorbic acid2Recruiting1
DB11595Atezolizumab2Recruiting1
DB06626Axitinib2Active Not Recruiting1
DB06626Axitinib2Recruiting2
DB06626Axitinib2Terminated1
DB00112Bevacizumab2Completed2
DB00112Bevacizumab2Recruiting1
DB00112Bevacizumab2Terminated1
DB00112Bevacizumab2Unknown Status1
DB00188Bortezomib2Terminated1
DB08875Cabozantinib2Not Yet Recruiting1
DB08875Cabozantinib2Recruiting3
DB01101Capecitabine2Completed1
DB14917Ceralasertib2Recruiting1
DB00997Doxorubicin2Completed2
DB06486Enzastaurin2Completed1
DB01590Everolimus2Completed2
DB01590Everolimus2Terminated1
DB00099Filgrastim2Completed1
DB00441Gemcitabine2Completed2
DB14865Human interleukin-22Terminated2
DB00034Interferon Alfa-2a, Recombinant2Completed1
DB00105Interferon alfa-2b2Unknown Status1
DB06186Ipilimumab2Withdrawn1
DB11740MK-17752Recruiting1
DB09035Nivolumab2Active Not Recruiting1
DB09035Nivolumab2Recruiting4
DB09035Nivolumab2Withdrawn1
DB09074Olaparib2Recruiting2
DB06589Pazopanib2Active Not Recruiting1
DB06589Pazopanib2Recruiting2
DB06589Pazopanib2Terminated1
DB06589Pazopanib2Unknown Status1
DB00019Pegfilgrastim2Completed1
DB05578Ramucirumab2Completed1
DB14765Rivoceranib2Not Yet Recruiting1
DB00398Sorafenib2Completed1
DB00398Sorafenib2Recruiting2
DB00398Sorafenib2Terminated3
DB01268Sunitinib2Active Not Recruiting2
DB01268Sunitinib2Completed4
DB01268Sunitinib2Recruiting3
DB01268Sunitinib2Terminated2
DB01268Sunitinib2Unknown Status1
DB15232Telaglenastat2Recruiting1
DB06287Temsirolimus2Active Not Recruiting1
DB06287Temsirolimus2Completed1
DB00624Testosterone2Recruiting1
DB11800Tivozanib2Completed1
DB15140Bempegaldesleukin3Recruiting1
DB08875Cabozantinib3Recruiting1
DB00531Cyclophosphamide3Completed1
DB06643Denosumab3Recruiting1
DB05928Dovitinib3Completed1
DB01590Everolimus3Completed1
DB14865Human interleukin-23Completed1
DB05258Interferon alfa3Completed1
DB06186Ipilimumab3Active Not Recruiting1
DB00603Medroxyprogesterone acetate3Completed1
DB09035Nivolumab3Active Not Recruiting1
DB09035Nivolumab3Recruiting2
DB00020Sargramostim3Completed1
DB00398Sorafenib3Completed2
DB01268Sunitinib3Active Not Recruiting1
DB01268Sunitinib3Completed1
DB01268Sunitinib3Recruiting1
DB01268Sunitinib3Terminated1
DB00399Zoledronic acid3Recruiting1
DB01590Everolimus4Completed2
DB01268Sunitinib4Terminated3
DB06589PazopanibNot AvailableActive Not Recruiting1
DB06589PazopanibNot AvailableCompleted1
DB01268SunitinibNot AvailableActive Not Recruiting1
DB01268SunitinibNot AvailableCompleted2
DB01268SunitinibNot AvailableRecruiting1